Ginkgo Bioworks: A Long Way To Go

11:19am, Tuesday, 21'st Nov 2023
Ginkgo Bioworks' Q3 results were relatively poor due to the difficult macro environment and the winding down of its COVID testing business. While Ginkgo's Cell Engineering business has enormous potent
Ginkgo Bioworks is successfully scaling its customer base. It's also making some progress towards profitability.
Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative insulation.
Ginkgo Bioworks Holdings Inc. (NYSE:DNA ) Q3 2023 Results Conference Call November 8, 2023 5:30 PM ET Company Participants Megan LeDuc - Manager of Investor Relations Jason Kelly - Founder, CEO & Dire
No investor likes a big earnings miss. While the biotech beat on the top line for its third quarter, that bottom-line whiff was glaring.
Ark Invest bought shares of Toast, Ginkgo Bioworks, and Robinhood Markets on Wednesday. The three stocks fell as much as 14% on Wednesday after disappointing quarterly results.

3 No-Brainer Stocks to Buy With $50 Right Now

05:00am, Tuesday, 31'st Oct 2023
No-brainer buys offer you a compelling future growth story for a great price. The idea is to make a small investment today and hold on for the long term when your patience could pay off.

Porter's 5 Forces Suggest That Ginkgo Is A Buy

05:49am, Wednesday, 25'th Oct 2023
Ginkgo Bioworks is analyzed based on Porter's Five Forces framework for competitive dynamics. The threat of competition in Ginkgo's R&D discovery business is low due to its unique offerings and limite
Ginkgo Bioworks boasts an impressive roster of clients, partners, and executives. The company's revenue is unpredictable while its cash burn is hard to ignore.
Ark Invest bought shares of Roku, Ginkgo Bioworks, and Archer Aviation on Wednesday. Roku hit a three-month low on Wednesday after an analyst lowered his price target on the shares a day earlier.
Famous investor Cathie Wood has been buying up shares of Ginkgo Bioworks over the past year. The company's revenue has climbed in recent years, but the share price hasn't followed.
There are a couple of stocks in the healthcare sector that could climb more than 100%, according to consensus estimates from Wall Street analysts. Analysts expecting CRISPR Therapeutics to launch its
Ginkgo Bioworks' stock price has been volatile due to mixed Q2 earnings, partnership announcements, and concerns about the macro environment. Antheia recently achieved a successful full-scale producti

3 Biotech Stocks Ready to Break Out in 2024

09:00am, Saturday, 07'th Oct 2023
While the S&P 500 remains up on the year, the biotech sector is down. Even though the broader market is showing signs of strength in areas like AI and automation, those trends haven't benefited biotec
Although the innovation space may be on the verge of a broader correction, certain ideas may pop higher, which brings us to Cathie Wood stocks to make you rich. One of the most respected names on Wall
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE